image
Healthcare - Biotechnology - NASDAQ - US
$ 28.54
-6.36 %
$ 173 M
Market Cap
-14.41
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one MNPR stock under the worst case scenario is HIDDEN Compared to the current market price of 28.5 USD, Monopar Therapeutics Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one MNPR stock under the base case scenario is HIDDEN Compared to the current market price of 28.5 USD, Monopar Therapeutics Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one MNPR stock under the best case scenario is HIDDEN Compared to the current market price of 28.5 USD, Monopar Therapeutics Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
0 REVENUE
0.00%
-8.83 M OPERATING INCOME
16.19%
-8.4 M NET INCOME
20.10%
-7.86 M OPERATING CASH FLOW
-8.71%
4.93 M INVESTING CASH FLOW
200.19%
2.03 M FINANCING CASH FLOW
6066.85%
0 REVENUE
0.00%
-1.57 M OPERATING INCOME
11.96%
-1.3 K NET INCOME
99.92%
-4.4 B OPERATING CASH FLOW
-262447.35%
986 K INVESTING CASH FLOW
40782.21%
-16.5 K FINANCING CASH FLOW
-66.69%
Balance Sheet Monopar Therapeutics Inc.
image
Current Assets 7.33 M
Cash & Short-Term Investments 7.27 M
Receivables 0
Other Current Assets 66.4 K
Non-Current Assets 12.6 K
Long-Term Investments 0
PP&E 12.6 K
Other Non-Current Assets 0
Current Liabilities 1.76 M
Accounts Payable 1.76 M
Short-Term Debt 0
Other Current Liabilities 0
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall Monopar Therapeutics Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 8.83 M
Operating Income -8.83 M
Other Expenses -429 K
Net Income -8.4 M
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-150.37% ROE
-150.37%
-114.39% ROA
-114.39%
-158.05% ROIC
-158.05%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Monopar Therapeutics Inc.
image
Net Income -8.4 M
Depreciation & Amortization 8.83 M
Capital Expenditures 0
Stock-Based Compensation 1.9 M
Change in Working Capital -1.35 M
Others -20.4 K
Free Cash Flow -7.86 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Monopar Therapeutics Inc.
image
Wall Street analysts predict an average 1-year price target for MNPR of $29.5 , with forecasts ranging from a low of $22 to a high of $37 .
MNPR Lowest Price Target Wall Street Target
22 USD -22.92%
MNPR Average Price Target Wall Street Target
29.5 USD 3.36%
MNPR Highest Price Target Wall Street Target
37 USD 29.64%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Monopar Therapeutics Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
25.2 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
100 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Oct 28, 2024
Bought 25.2 K USD
Radhakrishnan Karthik
Chief Financial Officer
+ 1550
16.25 USD
7 months ago
Jun 20, 2024
Bought 15.3 K USD
Cittadine Andrew
Chief Operating Officer
+ 20508
0.7438 USD
7 months ago
Jun 18, 2024
Bought 10.3 K USD
Cittadine Andrew
Chief Operating Officer
+ 12000
0.86 USD
7 months ago
Jun 17, 2024
Bought 10.8 K USD
Cittadine Andrew
Chief Operating Officer
+ 12000
0.8999 USD
7 months ago
Jun 14, 2024
Bought 11.2 K USD
Cittadine Andrew
Chief Operating Officer
+ 12000
0.9313 USD
7 months ago
Jun 13, 2024
Bought 10.9 K USD
Cittadine Andrew
Chief Operating Officer
+ 12000
0.91 USD
7 months ago
Jun 04, 2024
Bought 9.36 K USD
Cittadine Andrew
Chief Operating Officer
+ 12000
0.78 USD
7 months ago
Jun 03, 2024
Bought 9.12 K USD
Cittadine Andrew
Chief Operating Officer
+ 12000
0.76 USD
7 months ago
May 31, 2024
Bought 7.73 K USD
Cittadine Andrew
Chief Operating Officer
+ 12000
0.6443 USD
7 months ago
May 30, 2024
Bought 7.68 K USD
Cittadine Andrew
Chief Operating Officer
+ 12000
0.6397 USD
7 months ago
May 29, 2024
Bought 7.64 K USD
Cittadine Andrew
Chief Operating Officer
+ 12000
0.6369 USD
2 years ago
Nov 15, 2022
Bought 31.5 K USD
Cittadine Andrew
Chief Operating Officer
+ 10000
3.15 USD
2 years ago
Nov 14, 2022
Bought 18.2 K USD
Cittadine Andrew
Chief Operating Officer
+ 6053
3 USD
3 years ago
Feb 11, 2021
Sell 565 K USD
Tactic Pharma LLC
- 42467
13.3 USD
3 years ago
Feb 11, 2021
Sell 341 K USD
Tactic Pharma LLC
- 24224
14.09 USD
3 years ago
Feb 11, 2021
Sell 454 K USD
Tactic Pharma LLC
- 29996
15.12 USD
3 years ago
Feb 11, 2021
Sell 269 K USD
Tactic Pharma LLC
- 16384
16.44 USD
3 years ago
Feb 11, 2021
Sell 202 K USD
Tactic Pharma LLC
- 11929
16.9 USD
5 years ago
Dec 18, 2019
Bought 3.75 M USD
Hendricks Diane
+ 468750
8 USD
5 years ago
Dec 18, 2019
Bought 1 M USD
Tactic Pharma LLC
+ 125000
8 USD
5 years ago
Dec 18, 2019
Bought 1.25 M USD
Leo Karl
+ 156250
8 USD
5 years ago
Dec 18, 2019
Bought 2.51 K USD
Leo Karl
+ 313.75
8 USD
5 years ago
Dec 18, 2019
Bought 2.6 K USD
Tsuchimoto Kim R
+ 325
8 USD
7. News
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN Monopar stock skyrockets 384% in three months following a licensing deal with AstraZeneca for a late-stage Wilson Disease candidate. zacks.com - 2 weeks ago
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024 Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025. zacks.com - 3 weeks ago
Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways MNPR-101-Lu is being developed in a phase 1 study to target advanced solid tumor patients with uPAR expression. MNPR-101-Zr is being used as an imaging agent to determine which advanced solid tumor patients is likely to respond to MNPR-101-Lu in a phase 1 study. The global solid tumor cancer treatment market size is projected to hit around $532.42 billion by 2032; uPAR expression is high in a variety of types of solid tumors. seekingalpha.com - 3 weeks ago
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered offering of 798,655 shares of its common stock at an offering price of $23.79 per share. In addition to the shares sold in the registered offering, Monopar announced the concurrent pricing of a private placement of pre-funded warrants to purchase 882,761 shares of common stock at a purchase price of $23.789 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The gross proceeds to Monopar from the registered offering and private placement, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be $40 million. The offering is expected to close on or about December 23, 2024, subject to customary closing conditions. globenewswire.com - 4 weeks ago
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the first patient ever dosed with MNPR-101-Lu. This novel therapeutic radiopharmaceutical combines MNPR-101, Monopar's antibody that selectively targets the urokinase plasminogen activator receptor (uPAR), with the therapeutic radioisotope lutetium-177. uPAR is involved in tumor growth and metastasis, and is found in some of the most aggressive, deadly cancers, including pancreatic, ovarian, triple negative breast, and colorectal cancers. globenewswire.com - 1 month ago
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robinson, MD, Monopar's Chief Executive Officer, will participate in a fireside chat along with one-on-one meetings at the 36th Annual Piper Sandler Healthcare Conference. globenewswire.com - 1 month ago
3 Momentum Stocks Soaring Into 2025 and Beyond Investors favoring a short horizon and possessing a fair amount of risk tolerance sometimes look to stocks that have already been trending upward in an effort to capitalize on their momentum. This investment strategy often looks more toward price movement than it does the fundamentals of a company. marketbeat.com - 1 month ago
What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing' Monopar Therapeutics (MNPR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. zacks.com - 1 month ago
What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing' Monopar Therapeutics (MNPR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. zacks.com - 1 month ago
Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus Monopar Therapeutics is a clinical-stage biotech focused on radiopharmaceuticals for oncology and recently expanded into rare diseases with ALXN-1840. MNPR's oncology pipeline includes MNPR-101-Zr for diagnostics and MNPR-101-Lu/Ac for therapeutic applications, both in the early development stages. ALXN-1840, a Phase 3 asset for Wilson disease, diversifies MNPR's portfolio but does not directly complement its oncology focus. seekingalpha.com - 1 month ago
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare Disease Two Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid Cancers globenewswire.com - 2 months ago
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock WILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the closing of its previously announced best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the placement agent's fees and other offering expenses payable by the Company. globenewswire.com - 2 months ago
8. Profile Summary

Monopar Therapeutics Inc. MNPR

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 173 M
Dividend Yield 0.00%
Description Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Contact 1000 Skokie Boulevard, Wilmette, IL, 60091 https://www.monopartx.com
IPO Date Dec. 19, 2019
Employees 9
Officers Dr. Christopher M. Starr Ph.D. Co-Founder & Independent Executive Chairman of the Board Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc Co-Founder, Chief Executive Officer, President & Director Dr. Patrice P. Rioux M.D., Ph.D. Acting Chief Medical Officer Mr. Andrew J. Cittadine M.B.A. Chief Operating Officer Mr. Karthik Radhakrishnan CFA Chief Financial Officer, Principal Accounting Officer & Principal Financial Officer